[March 26, 2015]

Research and Markets: Ampio Pharmaceuticals's Optina (Macular Edema and Macular Degeneration) Drug Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/qwdcbc/optina_macular) has announced the addition of the "Optina (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.

Currently the ME and AMD (News - Alert) markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant chang in the treatment of AMD patients and have a positive impact on the market growth.

Optina is an orally-administered, ultra-low-dose capsule reformulation of the steroid danazol that is in Phase III of clinical development by Ampio Pharmaceuticals for the treatment of DME. An effective non-surgical drug treatment for DME is a high unmet need, and Optina is the only drug in late-phase development addressing this need.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Optina including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Optina for the top country from 2013 to 2023.

- Sales information covered for the US.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Macular Degeneration Overview

3.2 Macular Edema Overview

4 Disease Management

5 Competitive Assessment

6 Unmet Need and Opportunity

6.1 Overview

6.2 Treatment for Dry AMD

6.3 Longer-Acting Anti-VEGF Drug Therapy

6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD

6.5 Less Invasive Drug Formulations

6.6 Awareness and Earlier Patient Diagnosis

6.7 Home Monitoring of AMD Progression

7 Pipeline Assessment

8 Optina

9 Appendix

For more information visit http://www.researchandmarkets.com/research/qwdcbc/optina_macular

[ Back To TMCnet.com's Homepage ]